Determining the optimal strategy for stopping chronic proton pump inhibitor therapy in primary care patients: impact of on-demand use, adjustment of therapy or discontinuation. - PEPPER

Z Leuven0 个研究点目标入组 745 人开始时间: 2022年12月20日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•adults older than 18 years old, male and females, Patients on long-term (>12 weeks) chronic (daily) PPI use without therapy indication are eligible to participate.

•Patients on short-term (<12 weeks) PPI therapy, Patients not able to understand or be compliant with the study., Patients not on chronic PPI use (less than 80% intake), Patients with established long-term indication such as the presence of a grade C, D oesophagitis, a peptic ulcer, Barrett’s oesophagus or Zollinger-Ellison syndrome, Patients with chronic use of Gaviscon® or similar drugs based on magaldrate such as Riopan® and Gastricalm® (i.e. more than once a week for the last 2 months)., Patients with long term chronic use of NSAIDs (i.e. two or more weekly doses)., Patients with a history of gastric or oesophageal surgery., Patients with a major oesophageal disease such as achalasia, oesophageal spasm, or oesophageal involvement in systemic disease such as scleroderma or dermatomyositis., Patients with drug abuse and/or alcohol abuse, Women who are pregnant or lactating

发起方

Z Leuven